Action against Respondent, a biotechnology company, for alleged deficiencies in Internal Control over Financial Reporting (ICFR).  According to the SEC, Respondent disclosed ICFR as a material weakness in public filings but failed to take adequate steps to remedy disclosed weaknesses.  Respondent has agreed to pay a civil penalty of $250,000.

SEC Order

SEC Administrative Summary